Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
June 15, 2002Journal of Clinical Oncology

Superior Survival With Capecitabine Plus Docetaxel Combination Therapy in Anthracycline-Pretreated Patients With Advanced Breast Cancer: Phase III Trial Results

View Full Paper
Ask AI
Bookmark
Share

Authors

JOJoyce O’ShaughnessyBaylor University Medical CenterDMDavid MilesUlsan CollegeSVSvetislava J. VukeljaRoche (Switzerland)

Discussion

Loading...

Member takes

Implication

Key Points

Key points are not available for this paper at this time.

Cite This Study

O’Shaughnessy et al. (2002) studied this question.

synapsesocial.com/papers/6a1bc421b33628da419cd2bbhttps://doi.org/10.1200/jco.2002.09.002
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Enhancement of immunohistochemical reactivity for thymidine phosphorylase in breast carcinoma cells after administration of docetaxel as a neoadjuvant chemotherapy in advanced breast cancer patients.2000 · 54 citations
  2. 2Prospective Randomized Trial of Docetaxel Versus Mitomycin Plus Vinblastine in Patients With Metastatic Breast Cancer Progressing Despite Previous Anthracycline-Containing Chemotherapy1999 · 508 citations
  3. 3Population-Based Pharmacoeconomic Model for Adopting Capecitabine/Docetaxel Combination Treatment for Anthracycline-Pretreated Metastatic Breast Cancer2003 · 24 citations
  4. 4Are Anthracycline-Taxane Regimens the New Standard of Care in the Treatment of Metastatic Breast Cancer?2003 · 66 citations